EQS-News: BIO-Europe Spring® 2023 is only a few weeks away 06.03.2023, 14:00 Uhr von EQS News Jetzt kommentieren: 0

EQS-News: EBD Group / Key word(s): Conference
BIO-Europe Spring® 2023 is only a few weeks away

06.03.2023 / 14:00 CET/CEST
The issuer is solely responsible for the content of this announcement.


PRESS RELEASE

BIO-Europe Spring® 2023 is only a few weeks away

Munich, Germany – March 6, 2023. EBD Group is thrilled to reunite on March 20–22, 2023 in Basel, Switzerland. After being held digitally for the last three years, leading executives from around the world are eager to get back to face-to-face partnering. The numbers of participants are living proof! We are currently looking to welcome more than 3,000 attendees, making this the largest BIO-Europe Spring® to date.

Partnering is in full swing with 2,000+ meetings being requested per day. In addition, the event will cater to the needs of the entire value chain in the biotech and pharma sector. World-class workshops and panels, innovative company presentations, active exhibition and a variety of networking opportunities, all making this event an unrivalled forum for companies across the biotech network to meet and do business.

As joint regional hosts, Novartis and Roche, will lead the program on Monday, March 20, at the opening keynote session: “Ready to partner? – Let’s talk” with speakers Susanne Kreutz, Global Head Corporate and Business Development at Novartis and James Sabry, Global Head, Pharma Partnering at Roche, and moderator Melanie Senior, Healthcare Writer & Analyst at Nature Biotech, Evaluate IN VIVO.

Tuesday, March 21, will host the popular panel discussion “Day in the life of an experienced dealmaker” featuring Kinam Hong, Partner at Sofinnova Partners, Philippe Lopes-Fernandes, Executive VP, Chief Business Officer at IPSEN, and Nathalie ter Wengel, European Lead Worldwide Business Devlopment at Pfizer and moderators Anton Gueth, Managing Director at EVOLUTION Life Science Partners and Evonne Sepsis, Founder and Managing Director at ESC Advisors.

Tuesday will also feature the exciting return of the Startup Spotlight to BIO-Europe Spring®. This lively competition will offer a selected group of startup companies the opportunity for a 4-minute pitch and participate in a live feedback session with judge panel members Stephan Emmerth, Business Development & Operations, Therapeutic Innovation Basel Area at Baselaunch, Niharika Sharma, Principal at Roivant Sciences, and Karen Wagner Managing Partner at Ysios Capital Partners.

Additionally, high-level executives from pharma, biotech, and the investment sector are confirmed to participate in panels and fireside chats covering a wide range of topics including insights into the latest therapeutic innovations and challenges in the sector, in-depth discussions covering the current trends and learnings from business development in life science, as well as the opportunities partnerships bring with them.

Registration and event information are available online.

Additional links and information:

Follow BIO-Europe Spring® 2023 on Twitter @EBDGroup (hashtag: #BIOEuropeSpring) or LinkedIn

About EBD Group

EBD Group’s overriding mission is to help collaborations get started across the life science value chain. Our range of partnering conferences has grown to become the largest and most productive conference platform in the industry. Each one of our landmark events held in key life science markets around the world is powered by our state-of-the-art partnering software, partneringONE®, that enables delegates to efficiently identify and engage with new opportunities via one-to-one meetings. Today our events (BIO-Europe®, BIO-Europe Spring®, Asio Bio Partnering Forum, BioPharm America™, Biotech Showcase™, Asia Showcase, Digital Medicine & Medtech Showcase, ChinaBio® Partnering Forum, and BioEquity Europe) annually attract more than 15,000 senior life science executives who engage in over 50,000 one-to-one partnering meetings. These vital one-to-one engagements are the wellspring of deals that drive innovation in our industry. EBD Group is an Informa company. For more information, please visit www.ebdgroup.com.

Media Contacts:
MC Services AG
+49 89 2102280
contact@mc-services.eu

Karina Marocco
EBD Group
kmarocco@ebdgroup.com

 



06.03.2023 CET/CEST Dissemination of a Corporate News, transmitted by EQS News - a service of EQS Group AG.
The issuer is solely responsible for the content of this announcement.

The EQS Distribution Services include Regulatory Announcements, Financial/Corporate News and Press Releases.
Archive at www.eqs-news.com


1575557  06.03.2023 CET/CEST

fncls.ssp?fn=show_t_gif&application_id=1575557&application_name=news&site_id=boersennews
Kommentare (0) ... diskutiere mit.
Werbung

Handeln Sie Aktien bei SMARTBROKER+ für 0 Euro!* Profitieren Sie von kostenloser Depotführung, Zugriff auf 29 deutsche und internationale Börsenplätze und unschlagbar günstigen Konditionen – alles in einer innovativen, brandneuen App. Jetzt zu SMARTBROKER+ wechseln und durchstarten!

*Ab 500 EUR Ordervolumen über gettex. Zzgl. marktüblicher Spreads und Zuwendungen.

k.A. k.A. k.A. k.A.
k.A. k.A. k.A. k.A.
k.A. k.A. k.A. k.A.
Schreib den ersten Kommentar!

Dis­clai­mer: Die hier an­ge­bo­te­nen Bei­trä­ge die­nen aus­schließ­lich der In­for­ma­t­ion und stel­len kei­ne Kauf- bzw. Ver­kaufs­em­pfeh­lung­en dar. Sie sind we­der ex­pli­zit noch im­pli­zit als Zu­sich­er­ung ei­ner be­stim­mt­en Kurs­ent­wick­lung der ge­nan­nt­en Fi­nanz­in­stru­men­te oder als Handl­ungs­auf­for­der­ung zu ver­steh­en. Der Er­werb von Wert­pa­pier­en birgt Ri­si­ken, die zum To­tal­ver­lust des ein­ge­setz­ten Ka­pi­tals füh­ren kön­nen. Die In­for­ma­tion­en er­setz­en kei­ne, auf die in­di­vi­du­el­len Be­dür­fnis­se aus­ge­rich­te­te, fach­kun­di­ge An­la­ge­be­ra­tung. Ei­ne Haf­tung oder Ga­ran­tie für die Ak­tu­ali­tät, Rich­tig­keit, An­ge­mes­sen­heit und Vol­lständ­ig­keit der zur Ver­fü­gung ge­stel­lt­en In­for­ma­tion­en so­wie für Ver­mö­gens­schä­den wird we­der aus­drück­lich noch stil­lschwei­gend über­nom­men. Die Mar­kets In­side Me­dia GmbH hat auf die ver­öf­fent­lich­ten In­hal­te kei­ner­lei Ein­fluss und vor Ver­öf­fent­lich­ung der Bei­trä­ge kei­ne Ken­nt­nis über In­halt und Ge­gen­stand die­ser. Die Ver­öf­fent­lich­ung der na­ment­lich ge­kenn­zeich­net­en Bei­trä­ge er­folgt ei­gen­ver­ant­wort­lich durch Au­tor­en wie z.B. Gast­kom­men­ta­tor­en, Nach­richt­en­ag­en­tur­en, Un­ter­neh­men. In­fol­ge­des­sen kön­nen die In­hal­te der Bei­trä­ge auch nicht von An­la­ge­in­te­res­sen der Mar­kets In­side Me­dia GmbH und/oder sei­nen Mit­ar­bei­tern oder Or­ga­nen be­stim­mt sein. Die Gast­kom­men­ta­tor­en, Nach­rich­ten­ag­en­tur­en, Un­ter­neh­men ge­hör­en nicht der Re­dak­tion der Mar­kets In­side Me­dia GmbH an. Ihre Mei­nung­en spie­geln nicht not­wen­di­ger­wei­se die Mei­nung­en und Auf­fas­sung­en der Mar­kets In­side Me­dia GmbH und de­ren Mit­ar­bei­ter wie­der. Aus­führ­lich­er Dis­clai­mer